Committee advances bill to reduce prior‑authorization barriers for rare‑disease treatments
Senate Bill 39, a governor-sponsored measure to remove prior authorization requirements for certain on‑label and off‑label uses of FDA‑approved drugs treating rare diseases in the commercial market, received a unanimous due‑pass recommendation from the committee.
The full story
Senate Bill 39, presented as a governor-sponsored bill, would limit prior‑authorization barriers for people with rare diseases who need on‑label or off‑label uses of FDA‑approved medications in the commercial insurance market. The sponsor characterized rare diseases as those affecting fewer than 200,000 people in the U.S., citing definitions used by federal agencies.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
or